Home TMU FAQ Sitemap
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Indication
Institution
Department
Principal Investigator
Protocol Title
TMU-JIRB No. Protocol Title Indication Institution Department Principal Investigator Contact
N202009060 A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib (The SAVANNAH Study) Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Rong-Wei Jhou
0963969166
N202010052 A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Rong-Wei Jhou
0963969166
N202011026 A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Rong-Wei Jhou
0963969166
N202012007 A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03) Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Rong-Wei Jhou
0963969166
N202108070 An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04) Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Cing-Mei Chen
0970746956
N202110055 A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection (ADAURA2) Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Rong-Wei Jhou
0963969166
N202201004 A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure. Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Cing-Mei Chen
0970746956
N202202008 A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC 9) Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Cing-Mei Chen
0970746956
N202204040 A Randomized, Open-Label, Phase 2 Study to Evaluate OBI-833/OBI-821 in Combination with First-Line Erlotinib in Patients with EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Rong-Wei Jhou
0963969166
N202208028 A Phase III, Randomised, Open- label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato- DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combin ation With Platinum-based Chemotherapy for the First- line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionabl e Genomic Alterations (D926NC00001; AVANZAR) Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Rong-Wei Jhou
0963969166
1 2 3 4 5 6 7 8 9 10 11 12 13 / 13

TOP